All In Biotech

Drug Trial Radar · NCT04003389

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,831 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,831

Actual

Start

Jul 10, 2019

Primary completion

Jan 4, 2022

Study completion Jan 4, 2022

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jul 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the "adverse events." Those were the side effects that study participants had while they were in the study. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks. This study was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo). At weeks 2 and 4 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine were collected for laboratory tests. At some study visits, study participants completed questionnaires that were about their quality of life. At the first and last study visits, they had a dual-energy x-ray absorptiometry (DXA for short) test done. To measure bone loss in the hips and spine, DXA created pictures of the inside of these areas with low-dose x-rays. (The dose was approximately one-tenth of the amount of a normal chest x-ray.) Study participants who still had their uterus had 2 more tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. It used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have had a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agreed. The last check-up at the hospital or clinic was at 3 weeks after the last dose of study treatment.

Conditions

  • Hot Flashes

Interventions

  • fezolinetantDrug

    administered orally

  • placeboDrug

    administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
  2. Number of Participants With Mild, Moderate and Severe TEAETime frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
  3. Percentage of Participants With Endometrial HyperplasiaTime frame: Baseline Up to 52 weeks
  4. Percentage of Participants With Endometrial CancerTime frame: Baseline Up to 52 weeks

Locations

182 sites in 8 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research

    Andalusia, Alabama

  • Alabama Clinical Therapeutics, LLC

    Birmingham, Alabama

  • Alabama Clinical Therapeutics, LLC

    Birmingham, Alabama

  • Achieve Clinical Research, LLC

    Ensley, Alabama

  • Mesa Obstetricians and Gynecologists

    Mesa, Arizona

  • Medpharmics LLC

    Phoenix, Arizona

  • Precision Trials

    Phoenix, Arizona

  • Del Sol Research Management

    Tucson, Arizona

  • Visions Clinical Research - Tuscon

    Tucson, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • Hope Research Institute

    Canoga Park, California

  • Alliance Research Inc

    Canoga Park, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Grossmont Center for Clinical Research

    La Mesa, California

  • Downtown L.A. Research Center, Inc.

    Los Angeles, California

  • National Research Institute - Panorama

    Los Angeles, California

  • Excell Research

    Oceanside, California

  • Clinical Trials Research

    Sacramento, California

  • Northern California Research

    Sacramento, California

  • Wake Research Associates, LLC

    San Diego, California

  • Women's Healthcare Affiliates

    San Diego, California

  • CITrials, Inc

    Santa Ana, California

  • Millennium Clinical Trials

    Thousand Oaks, California

  • Women's Medical Group of Upland

    Upland, California

  • Bayview Research Group

    Valley Village, California

  • Downtown Women's Health Care

    Denver, Colorado

  • Horizons Clincial Research Center LLC

    Denver, Colorado

  • Coastal Connecticut Research, LLC

    New London, Connecticut

  • Emerson Clinical Research institute

    Washington D.C., District of Columbia

  • Olympian Clinical Research

    Clearwater, Florida

  • Precision Clinical Research

    Coral Springs, Florida

  • Nature Coast Clinical Research

    Crystal River, Florida

  • Avail Clinical Research, LLC

    DeLand, Florida

  • Universal Axon Clinical Research

    Doral, Florida

  • Fleming Island Center for Clinical Research

    Fleming Island, Florida

  • Clinical Physiology Associates

    Fort Myers, Florida

  • Florida Medical Research

    Gainesville, Florida

  • Vital Pharma Research Inc.

    Hialeah, Florida

  • Health Awareness

    Jupiter, Florida

  • Multi-Specialty Research Associates, Inc.

    Lake City, Florida

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.